Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 237 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... January 7, 2020 Celebrating 75 years of NHS cancer care July 5, 2023 Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... August 27, 2021 ESMO Breast Cancer Congress 2022 April 20, 2022 Load more HOT NEWS What can elephants teach us about cancer? German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Addressing Cancer Pain with Complementary Methods (Part 2) EMA Recommends Extending Indications for Durvalumab
